160 related articles for article (PubMed ID: 37111385)
1. The Effects of Prolonged Treatment with Cemtirestat on Bone Parameters Reflecting Bone Quality in Non-Diabetic and Streptozotocin-Induced Diabetic Rats.
Martiniakova M; Kovacova V; Mondockova V; Svik K; Londzin P; Folwarczna J; Soltesova Prnova M; Stefek M; Omelka R
Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111385
[TBL] [Abstract][Full Text] [Related]
2. Triglyceride-lowering effect of the aldose reductase inhibitor cemtirestat-another factor that may contribute to attenuation of symptoms of peripheral neuropathy in STZ-diabetic rats.
Prnova MS; Kovacikova L; Svik K; Bezek S; Elmazoğlu Z; Karasu C; Stefek M
Naunyn Schmiedebergs Arch Pharmacol; 2020 Apr; 393(4):651-661. PubMed ID: 31802170
[TBL] [Abstract][Full Text] [Related]
3. 3-Mercapto-5H-1,2,4-Triazino[5,6-b]Indole-5-Acetic Acid (Cemtirestat) Alleviates Symptoms of Peripheral Diabetic Neuropathy in Zucker Diabetic Fatty (ZDF) Rats: A Role of Aldose Reductase.
Soltesova Prnova M; Svik K; Bezek S; Kovacikova L; Karasu C; Stefek M
Neurochem Res; 2019 May; 44(5):1056-1064. PubMed ID: 30689163
[TBL] [Abstract][Full Text] [Related]
4. Cemtirestat, an aldose reductase inhibitor and antioxidant compound, induces ocular defense against oxidative and inflammatory stress in rat models for glycotoxicity.
Reihanifar T; Şahin M; Stefek M; Ceylan AF; Karasu Ç;
Cell Biochem Funct; 2023 Aug; 41(6):622-632. PubMed ID: 37272424
[TBL] [Abstract][Full Text] [Related]
5. General toxicity assessment of the novel aldose reductase inhibitor cemtirestat.
Prnová MŠ; Račková L; Kováčiková L; Balleková J; Viskupičová J; Micháliková S; Taşkoparan B; Elmazoğlu Z; Rižner TL; Karasu C; Banerjee S; Štefek M
Interdiscip Toxicol; 2019 Nov; 12(3):120-128. PubMed ID: 32210700
[TBL] [Abstract][Full Text] [Related]
6. Amylin and bone metabolism in streptozotocin-induced diabetic rats.
Horcajada-Molteni MN; Chanteranne B; Lebecque P; Davicco MJ; Coxam V; Young A; Barlet JP
J Bone Miner Res; 2001 May; 16(5):958-65. PubMed ID: 11341342
[TBL] [Abstract][Full Text] [Related]
7. The effects of vanadium treatment on bone in diabetic and non-diabetic rats.
Facchini DM; Yuen VG; Battell ML; McNeill JH; Grynpas MD
Bone; 2006 Mar; 38(3):368-77. PubMed ID: 16256449
[TBL] [Abstract][Full Text] [Related]
8. Antioxidant and triglyceride-lowering effects of vitamin E associated with the prevention of abnormalities in the reactivity and morphology of aorta from streptozotocin-diabetic rats. Antioxidants in Diabetes-Induced Complications (ADIC) Study Group.
Karasu C; Ozansoy G; Bozkurt O; Erdoğan D; Omeroğlu S
Metabolism; 1997 Aug; 46(8):872-9. PubMed ID: 9258267
[TBL] [Abstract][Full Text] [Related]
9. Pain Allaying Epalrestat-Loaded Lipid Nanoformulation for the Diabetic Neuropathic Pain Interventions: Design, Development, and Animal Study.
Vishwakarma VK; Paswan SK; Arora T; Verma RK; Yadav HN
Curr Drug Metab; 2022; 23(7):571-583. PubMed ID: 35950248
[TBL] [Abstract][Full Text] [Related]
10. The protective effects of silibinin in the treatment of streptozotocin-induced diabetic osteoporosis in rats.
Wang T; Cai L; Wang Y; Wang Q; Lu D; Chen H; Ying X
Biomed Pharmacother; 2017 May; 89():681-688. PubMed ID: 28273632
[TBL] [Abstract][Full Text] [Related]
11. Eldecalcitol, an Active Vitamin D
Takeda S; Saito M; Sakai S; Yogo K; Marumo K; Endo K
Calcif Tissue Int; 2017 Oct; 101(4):433-444. PubMed ID: 28624935
[TBL] [Abstract][Full Text] [Related]
12. Dietary xylitol supplementation prevents osteoporotic changes in streptozotocin-diabetic rats.
Mattila PT; Knuuttila ML; Svanberg MJ
Metabolism; 1998 May; 47(5):578-83. PubMed ID: 9591750
[TBL] [Abstract][Full Text] [Related]
13. The beneficial roles of insulin and parathyroid hormones in the treatment of experimentally induced diabetic osteoporosis in female rats: bone mineral density, morphometric and histological studies.
Abd El Aziz GS; Ramadan WS; El-Fark MO; Saleh HA
Folia Morphol (Warsz); 2016; 75(3):341-354. PubMed ID: 26711653
[TBL] [Abstract][Full Text] [Related]
14. SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice.
Thrailkill KM; Clay Bunn R; Nyman JS; Rettiganti MR; Cockrell GE; Wahl EC; Uppuganti S; Lumpkin CK; Fowlkes JL
Bone; 2016 Jan; 82():101-7. PubMed ID: 26211996
[TBL] [Abstract][Full Text] [Related]
15. Diabetic characteristics and alveolar bone loss in streptozotocin- and streptozotocin-nicotinamide-treated rats with periodontitis.
Kim JH; Lee DE; Choi SH; Cha JH; Bak EJ; Yoo YJ
J Periodontal Res; 2014 Dec; 49(6):792-800. PubMed ID: 24490978
[TBL] [Abstract][Full Text] [Related]
16. Glycine therapy inhibits the progression of cataract in streptozotocin-induced diabetic rats.
Bahmani F; Bathaie SZ; Aldavood SJ; Ghahghaei A
Mol Vis; 2012; 18():439-48. PubMed ID: 22355255
[TBL] [Abstract][Full Text] [Related]
17. Bone mineral density and composition in rat pregnancy: effects of streptozotocin-induced diabetes mellitus and insulin replacement.
Tein MS; Breen SA; Loveday BE; Devlin H; Balment RJ; Boyd RD; Sibley CP; Garland HO
Exp Physiol; 1998 Mar; 83(2):165-74. PubMed ID: 9568476
[TBL] [Abstract][Full Text] [Related]
18. Comparison of effects of vanadium absorbed by Coprinus comatus with those of inorganic vanadium on bone in streptozotocin-diabetic rats.
Wang G; He M; Yi P; Wang J; Li B; Li J; Fu Y; Bai L; Fu Q
Biol Trace Elem Res; 2012 Dec; 149(3):391-8. PubMed ID: 22549703
[TBL] [Abstract][Full Text] [Related]
19. Oxidative stress in diabetic rats induced by streptozotocin: protective effects of melatonin.
Montilla PL; Vargas JF; Túnez IF; Muñoz de Agueda MC; Valdelvira ME; Cabrera ES
J Pineal Res; 1998 Sep; 25(2):94-100. PubMed ID: 9755030
[TBL] [Abstract][Full Text] [Related]
20. Cardiac sympathetic neuropathy and effects of aldose reductase inhibitor in streptozotocin-induced diabetic rats.
Kurata C; Okayama K; Wakabayashi Y; Shouda S; Mikami T; Tawarahara K; Sugiyama T
J Nucl Med; 1997 Nov; 38(11):1677-80. PubMed ID: 9374332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
